


WHAT IS CLAIMED:

1. A 3-deoxy-D-myo-inositol analog having the formula:



wherein X is O or CH<sub>2</sub>; R<sup>1</sup> and R<sup>2</sup> are individually, (C<sub>1</sub>-C<sub>25</sub>) alkyl, (C<sub>6</sub>-C<sub>10</sub>) aryl, (C<sub>3</sub>-C<sub>8</sub>) cycloalkyl, (C<sub>2</sub>-C<sub>22</sub>) alkenyl, (C<sub>5</sub>-C<sub>8</sub>) cycloalkenyl, (C<sub>7</sub>-C<sub>32</sub>) aralkyl, (C<sub>7</sub>-C<sub>32</sub>) alkylaryl, (C<sub>9</sub>-C<sub>32</sub>) aralkenyl, (C<sub>9</sub>-C<sub>32</sub>) alkenylaryl or C(O)R<sup>3</sup>; and R<sup>3</sup> is (C<sub>1</sub>-C<sub>25</sub>) alkyl, (C<sub>6</sub>-C<sub>10</sub>) aryl, (C<sub>3</sub>-C<sub>8</sub>) cycloalkyl, (C<sub>2</sub>-C<sub>22</sub>) alkenyl, (C<sub>5</sub>-C<sub>8</sub>) cycloalkenyl, (C<sub>7</sub>-C<sub>32</sub>) aralkyl, (C<sub>7</sub>-C<sub>32</sub>) alkylaryl, (C<sub>9</sub>-C<sub>32</sub>) aralkenyl or (C<sub>9</sub>-C<sub>32</sub>) alkenylaryl; R<sup>4</sup> and R<sup>5</sup> are individually hydrogen or a phosphate group; or when R<sup>4</sup> or R<sup>5</sup> is not hydrogen, a pharmaceutically acceptable salt thereof.

2. (Once Amended) A method of treating cancer comprising administering a therapeutically effective amount of a compound to a subject according to claim 1.
3. The method of Claim 2, wherein said cancer is one that is characterized by cells that over-express the EGF and/or the PDGF receptor, cells that express a mutant ras, or cells that comprise a Bcr/Abl transfection.
4. The method of Claim 3, wherein said cancer is selected from the group consisting of colon, pancreatic, prostate, head and neck, breast, gastric, renal, brain and CML.